|
TAF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.99840144432528E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63602464908763E-12 |
| Normal-vs-Stage2 |
3.71924713249427E-13 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
9.070800E-01 |
| Stage1-vs-Stage3 |
2.960400E-02 |
| Stage1-vs-Stage4 |
9.566400E-02 |
| Stage2-vs-Stage3 |
1.632820E-01 |
| Stage2-vs-Stage4 |
1.846760E-01 |
| Stage3-vs-Stage4 |
9.855600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-15 |
| Normal-vs-AfricanAmerican |
1.52760000204921E-08 |
| Normal-vs-Asian |
7.84861065028508E-12 |
| Caucasian-vs-AfricanAmerican |
6.334200E-01 |
| Caucasian-vs-Asian |
5.710200E-01 |
| AfricanAmerican-vs-Asian |
9.683200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
5.10702591327572E-15 |
| Male-vs-Female |
5.987800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.18793863634892E-14 |
| Normal-vs-Age(41-60Yrs) |
1.62636570877339E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
1.58137999999308E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.805600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.308200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.773600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.563200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.139400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.848800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.655660E-03 |
| Classical-VS-Follicular |
4.529700E-02 |
| Classical-VS-Other |
2.955200E-01 |
| Classical-VS-Normal |
1.8508528043526E-12 |
| Tall-VS-Follicular |
1.740970E-01 |
| Tall-VS-Other |
8.217600E-01 |
| Tall-VS-Normal |
1.62492241884138E-12 |
| Follicular-VS-Other |
7.361200E-01 |
| Follicular-VS-Normal |
1.62947433324234E-12 |
| Other-VS-Normal |
9.73800000000358E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62636570877339E-12 |
| Normal-vs-N1 |
1.89848137210902E-14 |
| N0-vs-N1 |
4.789400E-01 |
|
|
